Category: Parkinson's Disease: Pathophysiology
Objective: We assessed the association of serum sphingosine-1-phosphate (S1P) levels with motor and cognitive symptoms in patients with Parkinson’s disease (PD).
Background: Treatment with sphingosine-1-phosphate (S1P) agonists confers neuroprotective effects in animal models of Parkinson’s disease (PD).
Method: S1P concentrations were analyzed with liquid chromatography-tandem mass spectrometry (LC-MS/MS) in serum of 196 PD patients and in 196 age- and sex-matched controls. Motor (UPDRS III, Hoehn&Yahr) and cognitive (MoCA) function were assessed at baseline. Follow-up data was available from 64 patients (median [IQR], 513 [381-677] days).
Results: S1P levels were lower in PD patients compared with controls, i.e. 1.75 [1.38-2.07] and 1.90 [1.59-2.18] µmol/l, respectively (P=0.001). In PD patients, lower S1P concentrations were associated with higher UPDRS III scores and Hoehn&Yahr stage. In the follow-up cohort, S1P concentrations below the median were associated with faster motor decline (hazard ratio: 4.78 [95% CI 1.98, 11.50]), but not with cognitive worsening.
Conclusion: Our observations reveal an association of S1P with PD.
To cite this abstract in AMA style:
C. Choe, C. Englisch, L. Niemann, S. Lezius, M. von Lucadou, K. Marmann, R. Böger, S. Peine, G. Daum, C. Gerloff, E. Schwedhelm. Sphingosine-1-phosphate, motor severity and progression in Parkinson’s disease (MARK-PD) [abstract]. Mov Disord. 2021; 36 (suppl 1). https://www.mdsabstracts.org/abstract/sphingosine-1-phosphate-motor-severity-and-progression-in-parkinsons-disease-mark-pd/. Accessed May 19, 2025.« Back to MDS Virtual Congress 2021
MDS Abstracts - https://www.mdsabstracts.org/abstract/sphingosine-1-phosphate-motor-severity-and-progression-in-parkinsons-disease-mark-pd/